Major molecular response in CML patients treated with tyrosine kinase inhibitors: The paradigm for monitoring targeted cancer therapy

Richard D. Press

Research output: Contribution to journalArticle

11 Scopus citations
Original languageEnglish (US)
Pages (from-to)744-749
Number of pages6
JournalOncologist
Volume15
Issue number7
DOIs
StatePublished - 2010

Keywords

  • BCR-ABL
  • Chronic myeloid leukemia
  • Imatinib
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this